| 1.98 0.09 (4.76%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.48 | 1-year : | 2.9 |
| Resists | First : | 2.13 | Second : | 2.48 |
| Pivot price | 1.67  |
|||
| Supports | First : | 1.4 | Second : | 0.95 |
| MAs | MA(5) : | 1.81 |
MA(20) : | 1.61 |
| MA(100) : | 1.53 |
MA(250) : | 2.13  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 87.1 |
D(3) : | 71.2 |
| RSI | RSI(14): 69.4 |
|||
| 52-week | High : | 3.86 | Low : | 0.95 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CDXS ] has closed above the upper band by 4.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 10% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.99 - 2 | 2 - 2 |
| Low: | 1.79 - 1.8 | 1.8 - 1.81 |
| Close: | 1.97 - 1.98 | 1.98 - 1.99 |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Mon, 06 Apr 2026
Analyst sentiment unchanged after Codexis (CDXS) earnings - MSN
Thu, 02 Apr 2026
CDXS Stock Price, Quote & Chart | CODEXIS INC (NASDAQ:CDXS) - ChartMill
Thu, 26 Mar 2026
Vanguard disaggregates holdings; Codexis Inc (NASDAQ: CDXS) shows 0 shares - Stock Titan
Sun, 15 Mar 2026
Short Interest in Codexis, Inc. (NASDAQ:CDXS) Grows By 26.2% - MarketBeat
Thu, 12 Mar 2026
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform (NASDAQ:CDXS) - Seeking Alpha
Thu, 12 Mar 2026
Stifel reiterates Codexis stock Buy rating on solid 2026 guidance - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 91 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 72.6 (%) |
| Shares Short | 10,770 (K) |
| Shares Short P.Month | 7,260 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | -62.5 % |
| Operating Margin | 35.8 % |
| Return on Assets (ttm) | -16.2 % |
| Return on Equity (ttm) | -74.9 % |
| Qtrly Rev. Growth | 81.3 % |
| Gross Profit (p.s.) | 0.09 |
| Sales Per Share | 0.77 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -3.97 |
| PEG Ratio | 0 |
| Price to Book value | 3.53 |
| Price to Sales | 2.55 |
| Price to Cash Flow | -9.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|